Histological Assessment of Respiratory Tract and Liver of BALB/c Mice Nebulized with Tocilizumab

dc.contributor.authorde Andres, Paloma Jimena
dc.contributor.authorFerreiro, Sergio
dc.contributor.authorFlores, Angela
dc.contributor.authorGarcia, Almudena
dc.contributor.authorHenriquez-Camacho, Cesar
dc.date.accessioned2025-07-18T07:41:49Z
dc.date.available2025-07-18T07:41:49Z
dc.date.issued2024-06-27
dc.description.abstractPulmonary drug delivery offers a minimally invasive and efficient method for treating lung conditions, leveraging the lungs' extensive surface area and blood flow for rapid drug absorption. Nebulized therapies aim to deliver drugs directly to the lung tissue. This study investigates the histological impact of nebulized tocilizumab-a monoclonal antibody targeting IL-6, traditionally administered intravenously for rheumatoid arthritis and severe COVID-19-on a murine model. Thirty BALB/c mice were nebulized with tocilizumab (10 mg, 5 mg, and 2.5 mg) and six controls were nebulized with saline solution. They were euthanized 48 h later, and their organs (lungs, nasal mucosa, and liver) were analyzed by a microscopic histological evaluation. The results indicate that all the mice survived the 48 h post-nebulization period without systemic compromise. The macroscopic examination showed no abnormalities, and the histopathological analysis revealed greater lung vascular changes in the control group than in the nebulized animals, which is attributable to the euthanasia with carbon dioxide. Additionally, increased alveolar macrophages were observed in the nebulized groups compared to controls. No significant histological changes were observed in the liver, indicating the safety of nebulized tocilizumab. In conclusion, these findings suggest the potential of nebulized tocilizumab for treating pulmonary inflammation, warranting further research to establish its efficacy and safety in clinical settings.
dc.identifier.citationde Andres PJ, Ferreiro S, Flores A, Garcia A, Henriquez-Camacho C. Histological Assessment of Respiratory Tract and Liver of BALB/c Mice Nebulized with Tocilizumab. Pharmaceutics. 2024 Jun 27;16(7):862.
dc.identifier.doi10.3390/pharmaceutics16070862
dc.identifier.other39065559
dc.identifier.urihttps://hdl.handle.net/10115/93317
dc.language.isoen
dc.publisherMDPI
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBALB/c
dc.subjectanimal model
dc.subjectmonoclonal antibody
dc.subjectnebulization
dc.subjecttocilizumab
dc.titleHistological Assessment of Respiratory Tract and Liver of BALB/c Mice Nebulized with Tocilizumab
dc.typeArticle

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
pharmaceutics-16-00862.pdf
Tamaño:
2.92 MB
Formato:
Adobe Portable Document Format